Hot Net Payout Yield Companies To Invest In Right Now

U.S. stocks are overvalued ��and have been for months. That is what six well-known measures of valuation show.

While that doesn�� mean a bear market is imminent, there is a high probability that investment returns over the next decade will be below average, according to Yale University economics professor and Nobel laureate Robert Shiller.

Best Cheapest Companies To Watch For 2015: Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Incorporated operates as a biotechnology company. It principally engages in the development and acquisition of royalty revenue generating assets. The company engages in the research, milestone, and royalty revenue activities resulting from its collaborations with pharmaceutical partners. The collaborations primarily include ongoing clinical programs at Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Merck & Co., Cephalon, Inc, and Celgene. These partnered product candidates are being studied for the treatment of indications, such as thrombocytopenia, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, osteoporosis, menopausal symptoms, and Alzheimer?s disease. Ligand Pharmaceuticals Incorporated receives royalties principally on sales of Avinza from Pfizer, Promacta from GlaxoSmithKline, and Viviant /Conbriza from Pfizer. The company through its subsidiary, CyDex Pharmaceuticals, Inc., offers four marketed products, as well as has one approved product, a portfolio of partnered drug development programs, an internal pipeline of proprietary drugs, and the Captisol drug formulation platform technology. Ligand Pharmaceuticals Incorporated was formerly known as Progenx Inc. and changed its name in 1989. The company was founded in 1987 and is based in La Jolla, California.

Advisors' Opinion:

• [By Garrett Cook]

  Healthcare shares dropped by 0.34 percent in the US market on Wednesday. Top losers in the sector included POZEN (NASDAQ: POZN), down 7.2 percent, and Ligand Pharmaceuticals (NASDAQ: LGND), off 5.5 percent.

• [By Louis Navellier]

  QCOR is a strong buy at the current price.

  Biotech Stocks to Buy: Ligand Pharmaceuticals (LGND)

  Ligand Pharmacuticals (LGND) is a biotech company that focuses on acquisition and development of royalty revenue generating assets in the United States. Ligand has relationships with most of the leading drug companies including GlaxoSmithKline (GSK), Merck (MRK), Bristol-Myers (BMY), Eli Lilly (LLY) and others.

Hot Net Payout Yield Companies To Invest In Right Now: Supertex Inc.(SUPX)

Supertex, Inc., together with its subsidiary, Supertex Limited, designs, develops, manufactures, and markets high voltage analog and mixed signal integrated circuits (IC) primarily in Asia, the United States, China, and Europe. The company offers high voltage analog multiplexer switches, pulsers, high-speed MOSFET drivers, and discrete high voltage MOSFETs and arrays for the medical electronics market. It also provides LED driver products, including linear regulators and switching regulators for general lighting in automotive, industrial, and consumer applications; and for backlighting in LCD TVs, monitors, and laptop screens. In addition, the company offers electroluminescent lamps for backlighting hand-held instruments, such as cell phone keypads, watches, monochrome flat screens, and MP3 players; and driver ICs for driving non-impact printers and plotters. Further, it provides high voltage amplifier ICs to drive optical micro-electro-mechanical systems (MEMS) for use in optical switching applications in the telecommunications market; high voltage electronic switch ICs for use in telephones; high voltage ICs for use as ring generators; and protection ICs for line cards. Additionally, the company offers ICs and DMOS devices primarily for various industrial applications. It markets and sells its products through direct sales personnel, independent sales representatives, and distributors primarily to original equipment manufacturers of electronic products. The company was founded in 1975 and is headquartered in Sunnyvale, California.

Advisors' Opinion:

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Monday’s session are AutoNavi Holdings Ltd.(AMAP), Dick's Sporting Goods Inc.(DKS) and Supertex Inc.(SUPX)

Hot Net Payout Yield Companies To Invest In Right Now: AVG Technologies NV (AVG)

AVG Technologies N.V. (AVG), incorporated on March 3, 2011, provides software and online services. The Company is primarily engaged in the development and sale of Internet security software and online service solutions branded under the AVG name. The Company�� solutions include software and online services, include security, personal computer (PC) management, online backup and other products. As of December 31, 2011, the Company had approximately 15 million subscription users. AVG�� portfolio consists of Anti-Virus suite, Internet Security suite, Premium Security suite, AVG Mobilation, AVG Threatlabs, Family Safety, TuneUp Utilities and PC Tuneup, LiveKive and MultiMi. On January 4, 2011, the Company acquired DroidSecurity Ltd. On March 3, 2011, the Company established AVG Holding Cooperatief U.A. On May 18, 2011, the Company acquired iMedix Web Technologies Ltd. In August 2011, it acquired TuneUp Software GmbH. On August 19, 2011, AVG Technologies GER GmbH acquired TuneUp Software GmbH. On October 31, 2011, AVG Technologies Holdings B.V. acquired AVG Distribution Switzerland AG. In November 2011, the Company acquired Bsecure Solutions, Inc. On January 13, 2012, AVG Technologies USA, Inc. acquired OpenInstall, Inc. In May 2013, AVG Technologies NV acquired online privacy organisation PrivacyChoice.

The Company�� products include AVG Internet Security, AVG Anti-Virus, AVG Email Server Edition, AVG File Server Edition, AVG Linux Server Edition, AVG Rescue CD and AVG Remote Administration. The Company�� subsidiaries include AVG Technologies USA Inc., AVG Technologies CZ, s.r.o., AVG Technologies UK Ltd, AVG Exploit Prevention Labs, Inc., AVG Technologies GER, GmbH, AVG Technologies FRA SAS, AVG Technologies HK, Limited, AVG (Beijing) Internet Security Technologies Company Limited, AVG Mobile Technologies Ltd, AVG Netherlands B.V., AVG Ecommerce CY Ltd, AVG Technologies Holding B.V., TuneUp Software GmbH, TuneUp Distribution GmbH, TuneUp Corporation and AVG Distribution Switzerland AG! .

The Company competes with Microsoft, Google, Apple, Qihoo, Tencent, Facebook, UniBlue, Symantec, Trend Micro, Avast!, Avira, Symantec, Carbonite, Dropbox, Intel Corporation, Trend Micro, Eset, Kaspersky Labs, Panda Software, Sophos, Rising, Kingsoft, Check Point and F-Secure.

Advisors' Opinion:

• [By Igor Novgorodtsev]

  InterActiveCorp (IACI) bought Ask.com for $1.85 billion in 2005. The new Perion will be worth only about 40% of that. After the merger, Perion will leapfrog its much larger rivals: Babylon and AVG (AVG). Finally, Perion should be able to increase its operating margins as it can spread its SG&A costs over a much larger base (Conduit EBITDA margin is 32% vs. Perion's 23%). Perion will keep its senior management team intact: Josef Mandelbaum will remain its CEO and Yacov Kaufman its CFO. Perion has successfully orchestrated a roll-up acquisitions of privately-held Sweetpacks and Smilebox, so I have high confidence that they know how to integrate a new business.

Hot Net Payout Yield Companies To Invest In Right Now: Orexigen Therapeutics Inc.(OREX)

Orexigen Therapeutics, Inc., a development stage company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed phase III clinical trials; and Empatic that has completed phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; and naltrexone is a treatment for alcohol and opioid addiction. The company?s Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide is for the adjunctive treatment of partial seizures, a form of epilepsy. The company has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave. Orexigen Therapeutics, Inc. was founded in 2002 and is based in La Jolla, California.

Advisors' Opinion:

• [By James Brumley]

  But, given the pharma industry’s migration towards this more potent class of medicines, MNTA stock has plenty working in its favor for the long haul.

  Orexigen Therapeutics (OREX)

  Think Arena Pharmaceuticals (ARNA) and VIVUS (VVUS) used up all weight loss drug enthusiasm when the two companies won approval for Belviq and Qsymia, respectively, back in 2012?

• [By Maxx Chatsko]

  Unfortunately, doctors have not been knocking down the doors to prescribe Qsymia, and I foresee a similar slow start for Belviq when it launches this June. This wasn't unexpected for the new treatments, but over time the prospects should brighten. Market research performed by Orexigen (NASDAQ: OREX  ) suggests that obesity prescriptions could grow 300% to 400% in the next five years from just 7.8 million in 2012. Given the obesity market's ability to support multiple blockbusters, investors may be wondering what other weight-loss therapies are being developed elsewhere in the industry. Here are three compounds in the pipeline that could become the future of the fight against obesity. �

• [By Brian Orelli]

  VIVUS' direct competitors in the obesity space both have large partners. Arena Pharmaceuticals (NASDAQ: ARNA  ) secured a marketing deal with Eisai to market Belviq, and Orexigen (NASDAQ: OREX  ) will have help from Takeda once its obesity drug, Contrave, is approved.